Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 1,635 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 1,635 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total value of $36,624.00. Following the completion of the sale, the chief financial officer directly owned 85,034 shares of the company’s stock, valued at $1,904,761.60. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Howard Horn also recently made the following trade(s):

• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.70, for a total value of $190,884.30.
• On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $23.56, for a total value of $72,117.16.
• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $36.38, for a total value of $112,086.78.

Ultragenyx Pharmaceutical Trading Down 4.1%

Shares of RARE opened at $22.07 on Wednesday. The company’s 50 day simple moving average is $23.82 and its 200-day simple moving average is $29.24. The firm has a market cap of $2.13 billion, a PE ratio of -3.78 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.41 and a 12-month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the previous year, the business posted ($1.39) earnings per share. The company’s revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Truist Financial dropped their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Leerink Partners reduced their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Bank of America dropped their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Jefferies Financial Group cut their target price on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Finally, Wells Fargo & Company decreased their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $68.29.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank raised its stake in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Elevation Point Wealth Partners LLC purchased a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $55,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional buying: several large funds have recently increased or initiated stakes (notably Norges Bank and Frazier Life Sciences), which supports a base of long‑term institutional demand and can help stabilize the float. Institutional Inflows
• Neutral Sentiment: Management presentation transcript from TD Cowen’s healthcare conference is available—useful for updating pipeline timelines and modeling but contains no new regulatory or commercial outcomes. TD Cowen Presentation Transcript
• Negative Sentiment: Heavy insider selling by multiple senior executives, including CEO Emil Kakkis (54,404 shares) and several EVPs/C‑suite officers selling material blocks at ~ $22.7–22.8—markets often view clustered executive sales as a negative near‑term sentiment signal. SEC filing for the CEO sale: Insider Sale SEC Filing
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and one class action has been filed alleging misstatements/omissions tied to setrusumab (class period Aug 3, 2023–Dec 26, 2025). Proliferating notices and a filed suit raise potential legal and financial exposure and are likely pressuring the stock. Example filing/notice: Class Action Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.